Nefopam Versus Ondansteron for Prevention of Post Spinal Shivering.

Sponsor
Saint-Joseph University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04870541
Collaborator
(none)
150
1
2
12
12.5

Study Details

Study Description

Brief Summary

Spinal anesthesia affects the homeostatic systems resulting in intraoperative hypothermia and subsequently shivering. In fact, shivering may be seen after this technique in 30 to 40% of cases . Ondansetron and Nefopam have been used to prevent intraoperative shivering . However, no prospective, randomized, double-blind study has been conducted to this date in order to compare nefopam with ondansetron in the prevention of post-spinal anesthesia shivering.

The primary objective of this prospective, randomized, double-blind study is to compare the incidence and intensity of shivering after spinal anesthesia for non-obstetric surgery in 2 groups of patients.

Group A: Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).

• Group B: Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)

Condition or Disease Intervention/Treatment Phase
  • Drug: Ondansetron 8mg
  • Drug: Nefopam Injectable Solution
Phase 4

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Comparative Study Between Nefopam and Ondansteron for Prevention of Post Spinal Shivering. A Randomized Controlled Trial.
Actual Study Start Date :
Dec 1, 2020
Anticipated Primary Completion Date :
Jun 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Patients receiving Ondansetron

Drug: Ondansetron 8mg
Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).

Active Comparator: Patients receiving Nefopam

Drug: Nefopam Injectable Solution
Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)

Outcome Measures

Primary Outcome Measures

  1. Incidence of shivering [Shivering score was noted every 15 minutes from drug administration up to 120 minutes.]

    Number of episodes of shivering and variation will be noted every 15 minutes from drug administration up to 120 minutes.

  2. Grade of shivering [Shivering score was noted every 15 minutes from drug administration up to 120 minutes.]

    Grades of shivering will be noted every 15 minutes from drug administration up to 120 minutes. Shivering will be graded : 0 = no shivering, 1= piloerection or peripheral vasoconstriction but no visible shivering, 2 = muscular activity in only one muscle group, 3 = muscular activity in more than one muscle group but not generalized shivering, 4 = shivering involving the whole body.

Secondary Outcome Measures

  1. Nausea/Vomitting [Every 15 minutes from drug administration up to 120 minutes]

    Number of episodes of nausea and/or vomiting during and after surgery.

  2. Hypotention/Bradycardia [Every three minutes from drug administration up to 120 minutes.]

    Hypotention: Number of episodes of hypotension SBP <90mmhg or <25% of baseline SBP in post spinal anesthesia until discharge from the PACU. Bradycardia: Number of episodes of bradycardia <50 / min post-spinal anesthesia until discharge from the PACU.

  3. Pain on injection site by analogue visual scale. [During administration of drug.]

    Pain upon administration of drug on site of injection will be assessed using the analogue visual scale .

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age between 18 and 65 years

  • scheduled for a surgery under spinal anesthesia

Exclusion Criteria:
  • pregnant or breastfeeding (for the women), if they are

  • Allergy to any of the drugs to be used

  • Long QT syndrome

  • Hepatic insufficiency

  • Renal failure

  • Parkinson's disease

  • Epilepsy

  • Glaucoma

  • Phenylketonuria

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universite Saint Joseph , Hotel Dieu de France Beirut Lebanon

Sponsors and Collaborators

  • Saint-Joseph University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Saint-Joseph University
ClinicalTrials.gov Identifier:
NCT04870541
Other Study ID Numbers:
  • HDF15891
First Posted:
May 3, 2021
Last Update Posted:
May 3, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 3, 2021